CVRx
CVRx specializes in heart failure treatment through its Barostim therapy, an innovative approach using an implantable device to stimulate baroreceptors in the neck, improving patient symptoms and exercise capacity.
Barostim Therapy for Heart Failure
CVRx offers Barostim therapy, an innovative treatment for symptoms of heart failure. This therapy electrically stimulates baroreceptors in the neck to help improve symptoms, enhance quality of life, and increase exercise capacity in patients. The therapy is supported by clinical data and has been the subject of pivotal trials, such as the BeAT-HF study, which assesses its effectiveness in heart failure patients.
Barostim NEO Device
The company's flagship product, Barostim NEO, is an implantable pulse generator designed to treat heart failure. This device works by delivering electrical impulses to baroreceptors, helping to regulate heart function and alleviate heart failure symptoms. Barostim NEO is a critical component of CVRx's offerings and has shown significant patient benefits in both clinical trials and real-world applications.
Patent and Design Holdings
CVRx holds a robust intellectual property portfolio, including 90 issued patents and registered industrial designs worldwide, with 51 patents in the United States. This extensive patent portfolio underscores the company's commitment to innovation and leadership in the field of heart failure treatment technologies.
Prior Authorization and Reimbursement Support
CVRx provides a prior authorization service to assist healthcare providers with the insurance processes related to Barostim therapy. Additionally, the company offers comprehensive reimbursement support for healthcare professionals. This includes coding and coverage information, as well as claims assistance, to ensure that patients can access and benefit from Barostim therapy with minimal administrative hurdles.
